Trial Profile
A Randomized Phase IIa Study of Vorinostat in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 09 May 2022
Price :
$35
*
At a glance
- Drugs Vorinostat (Primary)
- Indications Myelodysplastic syndromes
- Focus Adverse reactions; Therapeutic Use
- Sponsors Merck Sharp & Dohme Corp.
- 26 Jan 2010 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 28 Jul 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 10 Oct 2008 Status changed from recruiting to active, no longer recruiting, based on information from ClinicalTrials.gov.